Potential new drugs are assessed in pre-clinical in vivo studies to determine their safety profiles. The drugs are formulated in vehicles suitable for the route of administration and the physicochemical properties of the drug, aiming to achieve optimal exposure in the test species. The availability of safety data on vehicles is often limited (incomplete data, access restricted/private databases). Nineteen potentially useful vehicles that contained new and/or increased concentrations of excipients and for which little safety data have been published were tested. Vehicles were dosed orally once daily to HanWistar rats for a minimum of 28 days and a wide range of toxicological parameters were assessed. Only 30% (w/v) hydroxypropyl-ß-cyclodextrin was found unsuitable owing to effects on liver enzymes (AST, ALT and GLDH), urinary volume and the kidneys (tubular vacuolation and tubular pigment). 20% (v/v) oleic acid caused increased salivation and hence this vehicle should be used with caution. As 40% (v/v) tetraethylene glycol affected urinary parameters, its use should be carefully considered, particularly for compounds suspected to impact the renal system and studies longer than 1 month. There were no toxicologically significant findings with 10% (v/v) dimethyl sulphoxide, 20% (v/v) propylene glycol, 33% (v/v) Miglyol®812, 20% (w/v) Kolliphor®RH40, 10% (w/v) Poloxamer 407, 5% (w/v) polyvinylpyrrolidone K30 or 10% (v/v) Labrafil®M1944. All other vehicles tested caused isolated or low magnitude effects which would not prevent their use. The aim of sharing these data, including adverse findings, is to provide meaningful information for vehicle selection, thereby avoiding repetition of animal experimentation.

Using gas chromatography-high resolution mass spectrometry with selected ion detection, the concentrations of testosterone, 5alpha-dihydrotestosterone, androsterone, 5alpha-androstane-3alpha,17beta-diol, 5alpha-androstane-3beta,17alpha-diol and 5alpha-androstane-3beta,17beta-diol were measured in the dorsal and ventral prostates of two strains of golden hamster (Mesocricetus auratus) at various ages from 60 to 250 days. The tissue concentrations from a control strain were compared with those of the BIO 87.2 strain of hamster, the latter developing benign hyperplasia of the prostate between 90 and 120 days of age. Marked increases in the concentration of total 5alpha-androstanediols in both prostatic lobes of the BIO 87.2 strain were detected, with the highest level of over 345 nmol/g protein being found at 200 days of age. In comparison, the control strain showed a less pronounced increase in concentration at 150 days. Increases in total 5alpha-androstanediols were mainly associated with increases in the concentration of 5alpha-androstane-3alpha,17beta-diol. Concentrations of testosterone in prostatic tissue were also found to increase in the BIO 87.2 animals with peak values being seen at 200 days. Increases in concentration of androsterone were observed by 150 days and these levels were maintained up to 250 days of age. Control animals showed no comparable increases in testosterone and androsterone during the time-course studied. Surprisingly, no significant variation in 5alpha-dihydrotestosterone concentration was detected in either strain from 60 to 250 days although levels were slightly but consistently higher in the BIO 87.2 strain. There were no significant fluctuations in any of the androgens assayed either before or during tumour development. The increases in 5alpha-androstane-3alpha,17beta-diol, testosterone and androsterone were detected only after tumours had become established.

No abstract